Infla‑Med works to transform scientific insights into meaningful advances for patient care.
The Infla‑Med Centre of Excellence is committed to unravelling the pathophysiological processes that drive inflammatory diseases through multidisciplinary fundamental and translational research.
Building on this foundation, the 2026–2031 research programme focuses on: Bench‑to‑bedside investigation of regulated cell death pathways and barrier dysfunction. Together, Infla‑Med researchers aim to identify shared disease mechanisms and translate these insights into improved diagnostics and new therapeutic strategies.
To achieve this, we concentrate on three key processes that play a central role in inflammation:
- Cell death signalling – how cells die in a regulated way
- Barrier function – how organs like the gut, lungs, and vessels maintain their protective lining
- Immune modulation – how the immune system is activated or controlled
When any of these processes fail, inflammation can begin and eventually lead to disease. By studying these mechanisms in detail, we aim to better understand conditions such as cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), parasitic infection, metabolic dysfunction-associated steatotic liver disease (MASLD), and inflammatory bowel disease (IBD).
Infla‑Med brings together experts who share:
- Knowledge of designing and synthesising chemical tool compounds for identifying and inhibiting disease targets
- Research platforms for advanced in vitro and in vivo testing
- Disease models that help uncover disease mechanisms relevant for clinical application